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Excision of Ets by an inducible site-specific recombinase causes
differentiation of Myb–Ets-transformed hematopoietic progenitors
Fabio Rossi*, Kelly M. McNagny*, Colin Logie†, A. Francis Stewart†
and Thomas Graf*
Background: The Myb–Ets protein encoded by the E26 acute avian leukemia
virus is a paradigm for the function of fused transcriptional activator
oncoproteins. Myb–Ets transforms hematopoietic progenitor cells (Myb–Ets
progenitors, MEPs) that can be induced to differentiate into eosinophilic and
myeloid cells by the activation of pathways involving Ras and/or protein kinase C.
The Ets portion of the fusion protein seems to be required to maintain the
multipotency of MEPs: MEPs transformed with a temperature-sensitive E26
mutant with a lesion in Ets (ts1.1) and shifted to the non-permissive temperature
predominantly form erythroid cells, but also form eosinophilic and myeloid cells.
This interpretation is complicated, however, by the observation that ts1.1-
transformed MEPs differ from MEPs transformed with wild-type E26 in that they
express erythroid and eosinophil markers even at the permissive temperature.
Results: In order to alleviate the problems associated with the use of
temperature-sensitive mutants we have designed a vector that allows the
inducible deletion of the Ets domain. To this end, we introduced FLP
recombinase target sites into the E26 virus on the 5′ and 3′ sides of ets and
included within the same retroviral vector sequences encoding an estrogen-
dependent FLP recombinase. This construct, termed FRV-3, is capable of
transforming cells to produce a phenotype indistinguishable from that of MEPs
obtained with wild-type virus. Hormone treatment of MEPs transformed with
FRV-3 induced erythroid differentiation in a subpopulation of the cells; this
subpopulation was found to have completely excised ets. However, in contrast to
previous results obtained with ts1.1-transformed MEPs, no differentiation along
the eosinophilic and myeloid lineages was seen in hormone-treated FRV-3-
transformed MEPs.
Conclusions: Our results demonstrate the feasibility of using a site-specific
recombinase to excise a fused oncoprotein domain encoded by a retrovirus.
More specifically, they show that the Ets portion of the Myb–Ets protein
selectively inhibits differentiation of MEPs along the erythroid lineage, and
suggest that Ets is also required for their differentiation along the eosinophil and,
possibly, myeloid lineages.
Background
A growing number of human neoplasms exhibit specific
chromosomal translocations that result in the formation of
fused proteins. These fusion proteins often contain parts
of transcription factors [1]. One-well studied example of
such a fused transcription factor-type oncoprotein is the
Myb–Ets protein encoded by the avian E26 retrovirus.
Myb and Ets are derived from the helix–turn–helix tran-
scriptional activators c-Myb and c-Ets-1 and, although
mutated, have retained their DNA-binding and transacti-
vation domains (for review see [2]). E26 virus causes an
acute leukemia in chickens and transforms hematopoietic
progenitors (Myb–Ets progenitors, MEPs) as well as
myeloblasts in vivo and in vitro [3]. Both Myb and Ets are
required, and must be fused, for leukemogenicity and for
in vitro transformation of MEPs; however, the transactiva-
tion domain of Ets is dispensable [4]. Although MEPs
express surface markers characteristic of thrombocytes,
and other markers characteristic of both erythroid and
thrombocytic cells, they exhibit properties of multipotent
progenitors. Thus, they can be induced to differentiate
along the eosinophil and myeloid lineages either by the
introduction of v-Ras or kinase-type viral oncogenes, or by
the activation of protein kinase C following treatment
with the phorbol ester TPA [3,5,6].
Using a temperature-sensitive mutant of E26 with a lesion
in the DNA-binding domain of Ets (ts1.1), we previously
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showed that when ts1.1-transformed MEPs were shifted
from 37 °C (the permissive temperature) to 42 °C (the
non-permissive temperature) they differentiate along the
erythroid lineage, with some clones also differentiating
along the myelomonocytic and eosinophil lineages [6].
Because the in vitro DNA-binding capacity of the Ets
domain is inactivated at 42 °C [6], these results suggested
that Ets DNA-binding activity of the fusion oncoprotein is
required to maintain the multipotency of MEPs. A caveat
to this interpretation comes from the observation that a
large proportion of ts1.1-transformed MEPs express
markers characteristic of erythroid cells and eosinophils
even at 37 °C, either because the DNA-binding capacity of
Ets is weakened at the permissive temperature [6] or
because the mutation also affects other functions of the
protein. We have therefore introduced the term ‘erythroid’
or ‘E’-MEPs for ts1.1-transformed MEPs to distinguish
them from the ‘thrombocytic’ or ‘T’-MEPs transformed by
the wild-type E26 virus [5,7]. Therefore the phenotypic
differences between MEPs transformed by E26 and ts1.1
do not allow us to distinguish unambiguously between the
possibilities that inactivation of Ets induces the commit-
ment of MEPs or that it merely triggers the maturation of
pre-committed erythroid/eosinophil cells.
Here we have re-examined the role of Ets by entirely
deleting it from MEPs transformed with Myb–Ets. For
this purpose we have developed a novel approach, consist-
ing of the introduction within the retroviral vector of two
FLP recombinase recognition sites flanking ets and the
inclusion within the same vector of the sequence encod-
ing a hormone-inducible FLP recombinase. The results
show that hormone treatment of MEPs transformed by
this construct leads to the excision of ets and differentia-
tion of the cells along the erythroid lineage.
Results
We constructed a bicistronic retroviral vector encoding
both Gag–Myb–Ets and a fusion protein made up of the
yeast FLP recombinase and the hormone-binding domain
of the human estrogen receptor (FLP–ER) [8]. In addit-
ion, we introduced a minimal FLP recombinase target
site in frame between myb and ets and a second minimal
target site 3′ to the sequence encoding the recombinase,
in a construct called FRV-3 (Fig. 1a). Once activated by
hormone treatment the recombinase should excise the ets
and FLP–ER sequences, producing a structure corresp-
onding to the one shown at the bottom of Figure 1a. 
To determine whether FRV-3 was capable of transforming
hematopoietic cells, 2-day-old chicken embryos, which
contain a large number of E26 target cells, were infected
with the construct and seeded in semisolid medium at
37 °C. The yields of MEPs and myeloblast colonies were
similar to those obtained with the wild-type virus. Several
MEP-type FRV-3-expressing colonies were isolated one
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Figure 1
Structure of the E26–recombinase vector and detection of hormone-
induced recombination. (a) Proviral structure of FRV-3, an E26 virus
encoding an inducible FLP recombinase and a minimal FLP target site
(mFRT). The coding regions are boxed. LTR, long terminal repeats;
IRES, internal ribosome entry site; FLP–ER, FLP recombinase fused
with the hormone-binding domain of the human estrogen receptor.
Hormone-induced activation of FLP–ER results in the deletion of both
ets and FLP–ER sequences, leaving a gag–myb-containing provirus
(bottom) in the host genome. The locations of the two PCR primers
(labelled 1 and 2) used to detect the recombination are indicated. (b)
PCR-based detection of hormone-induced recombination. Primary
FRV-3-transformed MEPs were treated with 10–6 M b-estradiol (b-E2)
or 10–6 M of its antagonist ICI 182 780 (ICI) for 48 h, and genomic
DNA was prepared for PCR analysis. The three reactions on the left
are controls, in which oligonucleotide primers corresponding to an
internal gag–myb sequence yielded the expected 350 bp product
(labelled 1 in Fig. 1a) before and after hormone treatment. The three
lanes on the right show the presence of a 210 bp fragment (labelled 2
in Fig. 1a) detected, in the hormone-treated cells only, using primers
flanking the minimal FLP target sites. (In untreated cells, the distance
between the primers is more than 5 kb and cannot be detected.) The
lower band in the first three lanes of the gel represents an artefact; the
middle lane contains marker DNA. (c) Detection of hormone-induced
recombination by western blotting. Total cellular proteins were
extracted from four independent FRV-3-transformed MEP clones which
had either been treated for 5 days with 10–6 M ICI or left untreated.
The extracts were electrophoresed, blotted and probed with an anti-
Myb polyclonal antibody (a-Myb). To detect FLP–ER, the filter was
subsequently stripped and reprobed with the EF-3 monoclonal
antibody directed against the human estrogen receptor (a-HER).
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week after infection, expanded in liquid culture and
examined for the expression of a battery of lineage-
restricted cell-surface markers. They were found to
express the thrombocyte- and MEP-restricted MEP21 and
MEP26 antigens but none, or very little, of the erythroid
antigen JS4 [9], the eosinophil antigen EOS47 [10,11] and
the myeloid antigen MYL 51/2 [12]. They were therefore
indistinguishable from ‘T’-MEPs transformed by wild-
type virus and clearly different from the ‘E’-MEPs trans-
formed by the ts1.1 mutant.
Treatment of FRV-3-transformed MEP clones with either
the estrogen agonist b-estradiol, or the antagonist
ICI 182 780 (ICI), resulted in the appearance of a diagnos-
tic PCR product, following amplification of total genomic
DNA with primers flanking the expected recombination
junction (Fig. 1a,b). Cloning and sequencing of this PCR
fragment confirmed that the recombinase induced the
precise excision of the sequences encoding ets and
FLP–ER from the integrated proviral genome. In addition,
an 80 kDa Gag–Myb protein was detected in hormone-
treated, recombinase-expressing cells, which had resulted
from the excision of ets. However, in one particular clone
(clone 212), no Gag–Myb protein was detected. Blotting of
extracts from this clone with an antibody directed against
the human estrogen receptor showed that it no longer
expressed FLP–ER (Fig. 1c).
Concomitant with the loss of Ets, the cells began to
express a- and b-globin mRNA (Fig. 2a). When tested at
the single-cell level, all clones contained hemoglobin-
positive cells, ranging from 5 % to 20 % of the total popul-
ation at day 5 (Fig. 2b). A time course of hemoglobin
induction showed that the proportion of erythroid cells
reached a plateau 5–6 days after initiation of ICI treatment
(Fig. 2c). This plateau probably reflects a balance
between recombination-induced, growth-arrested erythro-
cytes and their continuous replacement by self-renewing
MEPs, which have not yet deleted Ets. To show that
hormone treatment did not induce erythroid differentia-
tion per se, we treated wild-type MEPs with b-estradiol or
ICI. Neither of these treatments led to an increase in
b-globin expression (data not shown).
In parallel with the emergence of hemoglobin-positive
cells in FRV-3 transformants, a subpopulation of cells
emerged that had lost expression of the cell-surface
markers MEP21 (Fig. 3a) and GPIIb-IIIa (a thrombocyte-
specific integrin also produced by MEP cells [5]); these
cells instead expressed the erythroid marker JS4. The cell-
surface expression of the JS4 antigen allowed us to deter-
mine whether the erythroid cells specifically lacked Ets, as
one might predict if the switch in phenotype was indeed
due to the Ets deletion. To this end, ICI-treated FRV-3
transformants were separated into JS4+ and JS4– fractions
by fluorescence-activated cell sorting (FACS; Fig. 3b) and
analyzed for the expression of Myb-containing proteins
(Fig. 3c). JS4+ cells (lane 4) exclusively expressed the
Gag–Myb protein, whereas JS4– cells (lane 3) contained
both Gag–Myb–Ets and reduced levels of Gag–Myb
Figure 2
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Hemoglobin expression in hormone-treated FRV-3 transformants. Cells
were cultured in the presence or absence of 10–6 M ICI in blastoderm
medium containing 1 % crude chicken myelomonocytic growth factor
(cMGF) and 5 % anemic chicken serum as a source of erythropoietin.
(a) Northern analysis of globin mRNA 5 days after ICI treatment using
probes specific for a- and b-globin mRNA [3]; a GAPDH probe was
used as a control. (b) Detection of hemoglobin-containing cells by acid
benzidine staining (black) of FRV-3-transformed clone 28. (c) Time
course of hemoglobin expression (benzidine staining) upon ICI
treatment of FRV-3-transformed clone 57 cells.
protein compared to unsorted cells (lane 2). The unex-
pected expression of Gag–Myb protein by cells in which
no change in phenotype had taken place can be explained
by assuming that there are cells present that have already
excised Ets, and that these cells still contain sufficient
levels of the undegraded Gag–Myb–Ets protein to block
maturation. This would also imply that the full-size
protein prevents MEPs from becoming erythroid even in
the presence of the truncated protein. 
To investigate whether the excision of Ets also induces the
differentiation of MEPs along the eosinophil and
myelomonocytic lineages, 12 clones transformed by FRV-3
were examined for the expression of various lineage-spe-
cific cell-surface markers following a 5-day treatment with
ICI (Fig. 4) or b-estradiol (data not shown). Whereas all
ICI-treated clones contained a subpopulation of JS4+ cells,
none contained eosinophils, as detected by a lack of
expression of the EOS47 antigen (Fig. 4a) and eosinophil-
specific peroxidase. They also did not contain myelomono-
cytic marker-positive cells, as detected by using antibodies
directed against the MYL 51/2 antigen (Fig. 4). These two
cell types could not be found even when the clones were
maintained for up to 12 days in the presence of the inducer
(data not shown). Although ets was excised in only a frac-
tion of hormone-treated FRV-3 cells, we think that the
absence of detectable eosinophils and myeloblasts is signi-
ficant, as these cells can proliferate when Ets is inactivated
in ts1.1-transformed MEPs [6] and should have a growth
advantage relative to the differentiated erythroid cells. To
verify that the FRV-3 transformants had not lost their
capacity to differentiate, three clones were treated with
20 nM of the phorbol ester TPA. As has been described
earlier for MEPs transformed with wild-type E26 [3], all of
the FRV-3-transformed MEP clones that were tested diff-
erentiated into eosinophils (Fig. 4b) and into low (but
significant) numbers of myeloblasts. 
The absence of EOS47- and MYL 51/2-positive cells in
ICI-treated FRV3-transformed MEPs might be due to the
drug’s interference with differentiation along these lin-
eages, rather than a consequence of ets excision. To test
this possibility, two multipotent MEP clones transformed
with ts1.1 were grown in the presence or absence of ICI at
37 °C or 42 °C and analyzed at day 6 for their content of
EOS47- and MYL 51/2-positive cells. The results in
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Figure 3
Expression of the erythroid cell-surface marker
JS4 in hormone-treated FRV-3-transformed
MEP cells. (a) Flow cytometric analysis of
lineage-specific cell-surface antigens. FRV-3-
transformed MEPs were cultured with or
without 10–6 M ICI for 6 days and stained with
monoclonal antibodies directed against JS4 or
MEP21. Control, cells stained with the anti-
Src monoclonal antibody 327 (a gift from S.
Courtneidge). The horizontal axis represents
relative fluorescence intensity (logarithmic
scale), the vertical axis relative cell number
(linear scale). (b) Analysis of Myb proteins in
JS4+ cells. The ICI-treated cells shown in (a)
were stained with the anti-JS4 antibody and
sorted by FACS. The recorded staining
profiles are represented by contour lines. The
horizontal axis represents cell size (linear
scale), the vertical axis JS4 fluorescence
intensity (logarithmic scale). (c) Western blot
analysis of Myb proteins in JS4+ and JS4– cell
populations. Extracts corresponding to
5 × 104 cells were electrophoresed, blotted
and probed with the anti-Myb antibody. Lane
1, untreated FRV-3-transformed cells. Lanes
2–4, ICI-treated FRV-3-transformed cells: lane
2, unsorted cells; lane 3, JS4– cells; lane 4,
JS4+ cells.
(a)
(b)
(c)
Untreated ICI treated
Unsorted Negatively sorted Positively sorted
Control
JS4
MEP21
Control
JS4
1 2 3 4
MEP21
p135Gag–Myb–Ets
p80Gag–Myb
870 Current Biology 1996, Vol 6 No 7
Figure 5 show that ICI does not interfere with differentia-
tion of MEPs along the eosinophil and myeloid lineages,
and even slightly enhances eosinophil differentiation.
Similarly, when ts1.1 cells were shifted to 42 °C for 6 days,
the level of erythroid differentiation was increased by ICI
and decreased by b-estradiol, as measured by benzidine
staining and by northern blotting for b-globin RNA (F.R.
and T.G., unpublished observations).
Discussion
Here, we have demonstrated the feasibility of producing
‘conditional’ alleles of protein subdomains in a retroviral
vector, using a novel approach based on the use of a site-
specific recombinase. The experiments described also
unambiguously demonstrate that the removal of Ets from
MEPs releases their differentiation block along the eryth-
roid lineage, thus ruling out the outgrowth of pre-commit-
ted erythroblasts. Our data support the notion that
wild-type E26 virus and ts1.1 transform the same target-cell
population and that these cells acquire different pheno-
types after transformation. This strongly argues against the
possibility that the two viruses transform different targets.
As E26-encoded Myb is, by itself, capable of inducing the
formation of large, mature erythroid colonies [13], the
induction of erythroid differentiation in MEPs following
Ets excision might reflect a reversal to the phenotype of
erythroid cells transformed by v-Myb only. Because our
earlier experiments showed that Myb and Ets efficiently
transform erythroid cells [13], the targeting technology
involving the FLP recombinase target site and the
FLP–ER fusion protein should now make it feasible to
determine whether rejoining Gag–Myb with Ets in eryth-
roblasts transformed by the two separately expressed
oncoproteins will force them to acquire MEP properties.
A comparison with the results obtained with MEPs trans-
formed by the ts1.1 mutant of E26 indicate that the Ets
portion of the fused oncoprotein has multiple functions in
Figure 4
Analysis of eosinophil and myelomonocytic differentiation in hormone-
treated FRV-3-transformed MEPs. (a) Recombinase-induced
differentiation. Twelve individually FRV-3-transformed MEP clones
were either not treated or treated for 5 days with 10–6 M ICI and
analyzed by FACS for the expression of lineage-specific cell-surface
antigens. JS4 is an erythroid-specific antigen, EOS47 an eosinophil-
specific antigen, and MYL 51/2 is a myeloid-specific antigen. The bars
represent the proportion of antigen-positive cells detected in individual
clones. The white bar represents clone 212 which, as shown in Fig.
1c, has lost FLP–ER expression. The clones were ranked according to
the percentage of JS4+ cells in the ICI-treated samples. The average
percentages (± standard deviation) of antigen-positive cells among the
12 recombinase-expressing clones is as follows. Untreated clones:
JS4, 1.1 ± 0.9; EOS47, 0.9 ± 0.9; MYL 51/2, 0.5 ± 0.3. ICI-treated
clones: JS4, 13.5 ± 7.8; EOS47, 0.9 ± 1.3; MYL 51/2, 0.5 ± 0.3. (b)
Effect of TPA-treatment of FRV-3-transformed MEPs. FRV-3-
transformed clone 2 cells were treated with or without 20 nM TPA for
5 days and analyzed by FACS for the expression of lineage-restricted
markers. The conditions of treatment and the antigens tested are
indicated.
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Effect of hormone treatment of ts1.1-transformed MEPs before and
after shift to the non-permissive temperature. Clone 10 cells
transformed by ts1.1 were incubated for a total of 6 days in the
presence or absence of 10–6 M ICI and analyzed by FACS for the
expression of lineage-restricted markers. Temperatures and antigens
tested are indicated.
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immature hematopoietic cells. Thus, whereas MEPs
transformed by wild-type E26 virus or by FRV-3 are
tightly blocked in their differentiation program, ts1.1-
transformed MEPs differentiate partially along the eryth-
roid and eosinophilic lineage at 37 °C and essentially
completely at 42 °C. The findings that the in vitro DNA-
binding capacity of the ts1.1 Ets DNA-binding domain is
weakened at room temperature and completely abolished
at 42 °C [6], and that hormone-treated FRV-3-transformed
MEPs also differentiate along the erythroid lineage foll-
owing loss of Ets, suggest that commitment to erythroid
differentiation requires the DNA-binding capacity of Ets.
In contrast, the finding that ts1.1-transformed MEPs
undergo eosinophil and myeloid differentiation upon
temperature shift, but that MEPs from which Ets is
deleted do not, suggests that Ets also has a DNA-indepen-
dent function that is required for maturation along these
lineages. As hormone-treated FRV-3-transformed MEPs
do not generate detectable numbers of myeloid cells, one
can speculate that a similar DNA-binding-independent
function of Ets is required for myeloid differentiation.
This explanation is, however, weakened by the following
three observations: first, not all ts1.1-transformed MEPs
can be induced to differentiate along the myeloid lineage
[6]; second, Ets could only be deleted from a fraction of
FRV-3-transformed MEPs; and third, the induction of
myeloid differentiation in FRV-3-transformed MEPs by
TPA treatment was found to be inefficient.
A possible DNA-independent function of Ets in eosinophil
differentiation could be to recruit one or more nuclear
protein(s) to Myb–Ets-bound promoters; these proteins
might modify the spectrum of target genes regulated by
the oncoprotein. This model is in part supported by our
recent identification of MafB, a bZip (basic region–leucine
zipper) transcription factor that binds to c-Ets-1 [14].
Whether or not MafB plays a role in lineage commitment
remains to be determined. Such a model is analogous to
the one proposed for the function of the E2a–Pbx fusion
oncoprotein that has been implicated in human B-cell
leukemia. In this chimeric transcription factor, the DNA-
binding domain of the homeodomain-containing Pbx
protein is dispensable for cell transformation. Instead, Pbx
is thought to modify the DNA-binding capacity of the
helix–loop–helix E2a protein by recruiting other homeo-
domain proteins to the promoter complex [15–17].
Retroviral vectors exploiting inducible recombination
strategies offer a powerful tool for the study of protein func-
tion by allowing deletion of an entire protein or specific
protein domains in live cells. This represents an alternative
to inactivating gene function by using temperature-sensi-
tive mutants and offers the advantages of rational design
and unequivocal result interpretation. Our data also illus-
trate the power of comparing both approaches. The poten-
tial limitation of FLP-mediated gene excision might be
overcome by using drug-resistance markers, allowing the
selection of cells in which recombination has taken place,
and by developing more efficiently inducible FLP vectors
(P.-O. Angrand, M. Nichols, C.L., F.R. and A.F.S., unpub-
lished observations) or CRE vectors [18]. Such improve-
ments to the retroviral oncogene–recombinase approach
may have more general applications, including in gene
therapy. Here it might become possible to first expand cells
through oncogene transformation and then ‘normalize’
them through oncogene excision.
Materials and methods
Viral constructs
FRV-3 was engineered to contain two modified minimal recombinase
target sites of 39 nucleotides flanking the 5′ end of the ets gene and
the 3′ end of the sequence encoding FLP–ER. The 5′ minimal target
site encodes 13 novel amino acids between positions 32 and 33 of
Ets, in a region which has been shown to be dispensable for MEP cell
transformation [4]. To obtain FRV-3, an oligonucleotide corresponding
to a minimal FLP target site (mFRT, CTAGAGAAGTTCCTATACTCTAG-
TAAGAATAGGAACTTCGAAGA) was inserted at the XbaI site at position
11 799 of pMI3-IRES. pMI3-IRES was obtained by cloning the PvuII
fragment encoding the encephalomyocarditis internal ribosome entry
site (IRES) from the plasmid pCITE2a (Novagen) in the blunted
Asp718 site at position 11 025 of pMI3; pM13 is an E26 virus with a
modified LTR sequence [19]. A second mFRT oligonucleotide
(CTAGTTCGAAGTTCCTATTCTCTAGTAAGTATAGGAACTTCT) was
inserted at the NheI site at position 9 425 of pMI3-IRES. To minimize
the size of the recombinase target site insertion, two of the three
repeats present in the wild-type target site were used [20,21]. The
FLP–ER gene was inserted as a NcoI–NotI fragment in the polylinker 3′
of IRES. The NcoI site was introduced into the FLP gene by PCR,
resulting in a Pro to Ala change at position 2 of the recombinase
amino-acid sequence.
Cells
All cells were derived from embryos of a White Leghorn chicken flock
maintained by Lohmann and Co., Cuxhaven, Germany. The Q2bn pack-
aging cell line [22] was grown in Dulbecco’s modified Eagle’s medium
containing 8 % fetal calf serum, 2 % chicken serum and 10 mM Hepes.
Transformed primary cells were grown in ‘blastoderm medium’ [3] with
or without approximately 10 U ml–1 crude cMGF [23].
Production of infectious virus and blastoderm transformation
assay
Blastoderm cells were obtained from 2-day-old chick embryos (stage
10–12) as previously described [3]. Viruses were produced by tran-
siently transfecting plasmids containing proviral sequences in the
Q2bn packaging cell line [22] by Ca3(PO4)2 precipitation. For infec-
tion, pools of 2-day-old chicken embryo cells were cocultivated with
mitomycin-C-treated, transfected Q2bn cells for 24 h, the non-adherent
cells removed and plated in 0.8 % methylcellulose-containing blasto-
derm medium. After 10 days, transformed colonies were picked and
expanded in liquid medium.
Antibodies and immunofluorescence
Mouse monoclonal antibodies directed against MEP21 [3,10], EOS47
[10,11], MYL 51/2 [12] were produced in this laboratory. The JS4 anti-
body was described by Schmidt et al. [9] and provided by H. Beug.
The EF-3 antibody directed against the human estrogen receptor [24]
was a kind gift from H. Gronemeyer and P. Chambon. Indirect immuno-
fluorescence was performed on living cells. Cells were incubated for
10–30 min with the first antibody, washed in medium, centrifuged as
described above and resuspended with fluorescein-labeled goat anti-
mouse second antibody. After an additional 10–30 min incubation, cells
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were washed twice, and resuspended in medium containing propidium
iodide at a final concentration of 5 mg ml–1. Samples were analyzed on a
Beckman FACScan fluorocytometer using live gating to exclude dead
cells. Cell sorting was performed with a Coulter Epics sorter.
Western blotting
Cells were lysed in a solution containing 0.1 % Triton X-100, 25 mM
Tris–HCl (pH 7.6), 1 mM EDTA (pH 8), 200 mM NaCl, 50 mM NaF,
0.1 mg ml–1 leupeptin, 1 mM PMSF and 1 % Trasylol (Bayer), the
extracts fractionated by SDS–PAGE and blotted onto Immobilon-P mem-
brane (Millipore). Immunodetection was performed by enhanced chemilu-
minescence (ECL; Amersham) as recommended by the manufacturer.
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